We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Psoriasis: from bed to bench and back.
- Authors
Garber, Ken
- Abstract
The article discusses advances in immunology such as psoriasis therapies approved by the U.S. Food and Drug Administration (FDA), most recent of which is Stelara (ustekinumab) by Johnson & Johnson's. It mentions the unique effectiveness of psoriasis drugs through biologics and the reliance of researchers on the bed-to-bench-and-back approach. It also notes the confirmation provided by genetics and animal experiments on the efficacy of Stelara in psoriasis when it is attacking the interleukin (IL)-23 cells.
- Subjects
UNITED States; IMMUNOLOGY; PSORIASIS treatment; SKIN diseases; UNITED States. Food &; Drug Administration; JOHNSON &; Johnson (Company)
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 7, p563
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt.1906